Cargando…

MGRS: DIAGNOSIS AND TREATMENT

Detalles Bibliográficos
Autor principal:	Bridoux, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Main Program
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171483/ http://dx.doi.org/10.1097/01.HS9.0000936056.25229.69

Ejemplares similares

TREATMENT AT RELAPSE: WHAT TO DO FIRST?
por: Mateos, Maria-Victoria
Publicado: (2022)

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES
por: Kastritis, E.
Publicado: (2023)

TREATMENT OF TRIPLE-CLASS REFRACTORY DISEASE: BEYOND IMMUNOTHERAPY
por: Gavriatopoulou, M.
Publicado: (2023)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023)

EARLY DETECTION AND SCREENING FOR MULTIPLE MYELOMA PRECURSORS
por: Thorsteinsdottir, S.
Publicado: (2023)

BONE DISEASE
por: Terpos, E.
Publicado: (2023)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE
por: Bladé, J.
Publicado: (2023)

HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?
por: Einsele, H.
Publicado: (2023)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

FROM BENIGN TO MALIGNANT DISEASE
por: Bolli, Niccolò
Publicado: (2022)

THE ATLAS INITIATIVE AND HOW TO IMPROVE ACCESS FOR PATIENTS
por: Morgan, Kate
Publicado: (2022)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

HOW TO TREAT UNFIT AND FRAIL PATIENTS
por: Cook, Gordon
Publicado: (2022)

DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
por: Ocio, Enrique M
Publicado: (2022)

LIGHT CHAIN DEPOSITION DISEASE
por: Vos, Josephine M.I.
Publicado: (2022)

BONE DISEASE
por: Terpos, Evangelos
Publicado: (2022)

EXTRAMEDULLARY DISEASE
por: Beksac, Meral
Publicado: (2022)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

IMMUNOTHERAPY
por: Einsele, Hermann
Publicado: (2022)

HOW TO TREAT HIGH RISK PATIENTS
por: Kaiser, Martin
Publicado: (2022)

CIRCULATING TUMOR CELLS
por: Paiva, Bruno
Publicado: (2022)

A compassionate imagery intervention for patients with persecutory delusions
por: Forkert, Ava, et al.
Publicado: (2022)

Cognitive appraisals of dissociation in psychosis: a new brief measure
por: Černis, Emma, et al.
Publicado: (2021)

Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis
por: Evans, Rachel, et al.
Publicado: (2021)

Understanding agoraphobic avoidance: the development of the Oxford Cognitions and Defences Questionnaire (O-CDQ)
por: Rosebrock, Laina, et al.
Publicado: (2022)

Crystalloid glomerulopathy in monoclonal gammopathy of renal significance (MGRS)
por: Vankalakunti, Mahesha, et al.
Publicado: (2014)

Program
Publicado: (2011)

Program
Publicado: (2011)

Program
Publicado: (2010)

Pauci-immune Crescentic Glomerulonephritis Due to MGRS Crystalline Nephropathy
por: Sharma, Shailendra, et al.
Publicado: (2019)

Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation
por: Nairz, Manfred, et al.
Publicado: (2016)

Rare skeletal disorders: a multidisciplinary postnatal approach to diagnosis and management
por: Walleczek, Nina-Katharina, et al.
Publicado: (2021)

ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromes: Recommendations for cardiovascular imaging
por: Saraste, Antti, et al.
Publicado: (2020)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Integrating interventional oncology in the treatment of liver tumors
por: Putzer, D., et al.
Publicado: (2018)

A treatment‐specific marginal structural Cox model for the effect of treatment discontinuation
por: Johnson, Dana, et al.
Publicado: (2022)

Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology
por: Ristl, Robin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_afi8bgnfopo1fktui57h6mfgvj